Thyme Care raises $125 million, pushing cancer care startup's valuation above $2 billion
- ID
- 20729
- Status
- summarized
- Published
- 04 Sep 2026, 4:01 AM
- Fetched
- 04 Sep 2026, 4:03 AM
- Provider
- CNBC Technology
- Category
- technology
- Original URL
- https://www.cnbc.com/2026/09/02/thyme-care-raises-125-million-cancer-startups-value-over-2-billion.html
- Source URL
- https://www.cnbc.com/id/19854910/device/rss/rss.html
Summary
- Score
- 2.5
- Created
- 04 Sep 2026, 4:04 AM
- Tags
- Audience
- saas_founders
What happened
Thyme Care, a US cancer care startup founded in 2020, raised $125 million in a Series E round at a valuation above $2 billion, roughly double its Series D valuation from less than a year ago. The round was led by Morgan Health with participation from Humana, CVS Health Ventures, a16z Bio + Health, and others. The company operates a virtual navigation platform for cancer patients and is forming a new parent company to address drug affordability and clinical trial access.
Why it matters
This is a US healthtech funding announcement with no direct impact on Malaysian or SEA builders. The only transferable signal is that virtual care navigation platforms remain fundable at scale, which matters only if you are building or investing in healthtech in Southeast Asia and want a comparable business model reference.
Discussion angle
Whether the virtual care navigation model Thyme Care uses has any viable analogue in Malaysia's healthcare system, given differences in payer structure and oncology infrastructure.